You are here

Mitsubishi Tanabe Pharma

Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease

BioSpace

Mon, 07/24/23 - 09:57 am

neurodegenerative disease

Alzheimer's disease

Axsome Therapeutics

BrainStorm Cell Therapeutics

Seelos Therapeutics

Parkinson's Disease

Mitsubishi Tanabe Pharma

Huntington's disease

Prilenia Therapeutics

11 drugs granted FDA fast track designation in 2022

Beckers Hospital Review

Wed, 08/24/22 - 10:55 pm

Agios Pharmaceuticals

Bristol Myers Squibb

BioXcel Therapeutics

Mycovia Pharmaceuticals

Phathom Pharmaceuticals

Mitsubishi Tanabe Pharma

SIGA technologies

Alnylam Pharmaceuticals

FDA approves oral formulation of old ALS drug, giving patients new treatment option in sorely needed field

Endpoints

Fri, 05/13/22 - 10:41 am

Mitsubishi Tanabe Pharma

Mitsubishi's Medicago readies for the second wave

EP Vantage

Fri, 05/28/21 - 11:13 am

Mitsubishi Tanabe Pharma

Salix grabs ex-Asia rights to Mitsubishi Tanabe autoimmune drug

Fierce Biotech

Thu, 04/25/19 - 10:37 am

Mitsubishi Tanabe Pharma

autoimmune disease

ulcerative colitis

Regeneron inks a $325M deal, selling Asian rights to a pain treatment

Fierce Biotech

Fri, 10/2/15 - 04:56 pm

Mitsubishi Tanabe Pharma

musculoskeletal pain

On a crash course with Celgene? Biogen inks a $544M autoimmune drug deal

Fierce Biotech

Wed, 09/9/15 - 08:12 am

autoimmune disease

Mitsubishi Tanabe Pharma

China Biotech In Review: Fundings For China-Affiliated Drug Companies

Seeking Alpha

Sun, 08/11/13 - 11:02 am

Shenogen Pharma

Zhongyuan Union Stem Cell Bioengineering

Mitsubishi Tanabe Pharma

HengHeKangJian Pharmaceutica

Komtur Pharmaceuticals

Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market

BioMedReports

Sat, 01/14/12 - 01:00 pm

Mitsubishi Tanabe Pharma